MAR 0 7 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED

· 3. '0 - 13

MAR 1 3 2003

Applicant(s):

Rabbani et al.

TECH CENTER 1600/29UU

Serial No.:

08/978,636

Group Art Unit: 1635

Filed:

November 25, 1997

Examiner: Mary M. Schmidt

For: No

NON-NATIVE POLYMERASE ENCODING

NUCLEIC ACID CONSTRUCT

527 Madison Avenue, 9th Floor New York, NY 10022-4304 March 7, 2003

FILED BY EXPRESS MAIL

Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§1.56 & 1.97-1.98

Dear Sirs:

Pursuant to the provisions of 37 C.F.R. §§1.97-1.98, and in full compliance with their duty of disclosure under 37 C.F.R. §1.56, Applicants, through their attorney, are bringing the following eighty-one (81) documents to the attention of the U.S. Patent and Trademark Office and the Examiner handling their above-identified application:

Elazar Rabbani et al. Serial No. 08/978,636

Filed: November 25, 1997

Page 2 (Information Disclosure Statement Under 37 C.F.R. §§1.56 & I.97-I.98 - March 7, 2003)

EXPRESS MAIL CERTIFICATE

"Express Mail" Label No. EL647884447US

Deposit Date

March 7, 2003

I hereby certify that this paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington DC 20231.

Ronald C. Fedus Reg. No. 32,567

RECEIVED MAR 1 3 2003

Elazar Rabbani et al. Serial No. 08/978,636

Filed: November 25, 1997

Page 3 (Information Disclosure Statement Under 37 C.F.R. §§1.56 & F.G. CENTER 1600/2900 - March 7, 2003)

MAR 0 7 2003

- Wu, G.Y. and Wu, C.H., U.S. Patent No. 5,166,320 issued November 24, 1992 [Exhibit 1];
- 2. Williams, D.A. and Patel, V.P., International Patent Application No. PCT/US95/03817 filed March 27, 1995, published as PCT Patent Application Publication Number WO 95/26200 published October 5, 1995 [Exhibit 2];
- 3. Ward, D.C. et al., U.S. Patent No. 4,687,732 issued August 18, 1987 [Exhibit 3];
- 4. Schwartz, D.A. et al., "Construction of a retrotransposition indicator, sequence using a neomycin resistance-encoding gene containing a functional intron," Gene 127:233-236 (1993) [Exhibit 4];
- 5. Dunn J.J. et al., "Targeting bacteriophage T7 RNA polymerase to the mammalian cell nucleus," Gene 68:259-266 (1988) [Exhibit 5];
- 6. Fuerst, T.R. et al., "Eukaryotic transient-expression system based on recombinatnt vaccinia virus that synthesizes bacteriophage T7 RNA polymerase," Proc. Nat Acad. Sci. U.S.A. 83: 8122-8126 (1986) [Exhibit 6];
- 7. Lieber. A. et al., "High level gene expression in mammalian cells by a nuclear T7-phage RNA polymerase," Nucleic Acids Research 17(21): 8485-8493 (1989) [Exhibit 7];
- 8. Lieber, A. et al., "[5] Stable High-Level Gene Expression in Mammalian Cells by T7 Phage RNA Polymerase," Methods in Enzymology 217:47-67 (1993)[Exhibit 8];
- 9. Davenloo, P. et al., "Cloning and expression of the gene for bacteriophage T7 RNA polymerase," Proc. Nat. Acad. Sci. U.S.A. 81: 2035-2039 (1984) [Exhibit 9];
- Morris, C.E. et al., "Cloning and expression of the bacteriophage T3 RNA 10. polymerase gene," Gene 41:193-200 (1986) [Exhibit 10];

Elazar Rabbani et al. Serial No. 08/978,636

Filed: November 25, 1997

Page 4 (Information Disclosure Statement Under 37 C.F.R. §§1.56 & I.97-I.98 – March 7, 2003)

- 11. Kotani, H. et al., "Nucleotide sequence and expression of the cloned gene of bacteriophage SP6 RNA polymerase," <u>Nucleic Acids Research 15(6):2653-2664 (1987) [Exhibit 11];</u>
- 12. Dubendorff, J.W. and Studier, F.W., "Creation of a T7 Autogene Cloning and Expression of the Gene for Bacteriophage T7 RNA Polymerase under Control of Its Cognate Promoter," <u>Journal of Molecular Biology</u> 219: 61-68 (1991) [Exhibit 12];
- 13. Dahlberg, J.E. and Lund, E., "The Genes and Transcription of the Major Small Nuclear RNAs," in <u>Structure and Function of Major and Minor Small Nuclear Ribonucleoprotein Particles</u>, Birnstiel, M. Ed., Springer Verlag, Berlin, Heidelberg, NY, London, Paris, Tokyo, pp. 38-70 (1988)) [Exhibit 13];
- 14. Zieve, G.W. and Sautereau, R.A., "Cell Biology of the snRNP Particles," Biochemistry and Molecular Biology 25(1):1-46 (1990) [Exhibit 14];
- 15. Izant, J.G. and Sardelli, A.D., "Antisense Inhibiton of RNA Splicing," in <u>Current Communications in Molecular Biology, Antisense RNA and DNA,</u> Melton, D.A., Ed., Cold Spring Harbor Laboratory, pp. 141-149 (1988) [Exhibit 15]
- 16. You, C-Y and Weiner, A.M., "A U1 Small Nuclear Ribonucleoprotein Particle with Altered Specificity Induces Alternative Splicing of an Adenovirus E1A mRNA Precursor," Molecular and Cellular Biology 9(8):3429-3437 (1989)] [Exhibit 16]
- 17. Chen, C.J. et al., "Inhibition of HIV-1 Replication by Novel Multitarget Ribozymes," Antisense Strategies, Annals of the New York Academy of Sciences 660:271-273 (1992) [Exhibit 17]
- 18. Zhou Z. et al., "Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-*tat* and *rev* hammerhead ribozymes," Gene 149:33-39 (1994) [Exhibit 18]
- 19. Lisziewicz, J. et al., "Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS," Proc. Natl. Acad. Sci. USA 90:8000-8004 (1993) [Exhibit 19]

Elazar Rabbani et al. Serial No. 08/978,636 Filed: November 25, 1997 Page 5 (Information Disclosure Statement Under 37 C.F.R. §§1.56 & I.97-I.98 - March 7, 2003) Husson, R.N. et al., "Phase I study of continuous-infusion soluble CD4 as a 20. single agent and in combination with oral dideoxyinosine therapy in children with symptomatic human immunodeficiency virus infection," The Journal of Pediatrics 121(4):621-633 (1992) [Exhibit 20] Yu, M. et al., "Progress towards gene therapy for HIV infection," Gene 21. Therapy 1:13-16 (1994) [Exhibit 21] Sczakiel, G. et al., "Tat- and Rev-Directed Antisense RNA Expression Inhibits 22. and Abolishes Replication of Human Immunodeficiency Virus Type 1: a Temporal Analysis," Journal of Virology 66(9):5576-5581 (1992) [Exhibit 22] Sczakiel, G. and Pawlita, M., "Inhibition of Human Immunodeficiency Virus 23. Type 1 Replication in Human T Cells Stably Expressing Antisense RNA," Journal of Virology 65(1):468-472 (1991) [Exhibit 23] Cotton, M. and Birnstiel, M.L., "Ribozyme mediated destruction of RNA in 24. vivo," The EMBO Journal 8(12):3861-3866 (1989) [Exhibit 24] Nichols, R. et al., "A universal nucleoside for use at ambiguous sites in DNA 25. primers," Nature 369:492-493 (1994)] [Exhibit 25] Eritja, R. et al., "Synthesis and properties of oligonucleotides containing 2'-26. deoxynebularine and 2'-deoxyxanthosine," Nucleic Acids Research 14(20):8135-8153 (1986) [Exhibit 26] Engelhardt D., et al., U.S. Patent No.5, 260,433 issued November 9, 1993 27. [Exhibit 27] Ward D.C. et al., U.S. Patent No. 4,711,955 issued December 8, 1987 28. [Exhibit 28] Engelhardt D. et al., U.S. Patent No. 5,241,060 issued August 31, 1993 29. [Exhibit 29] Stavrianoloulos, J., U.S. Patent No. 4,707,440 issued November 17, 1987 30. [Exhibit 30] Enz-53(D3)

Elazar Rabbani et al. Serial No. 08/978,636 Filed: November 25, 1997 Page 6 (Information Disclosure Statement Under 37 C.F.R. §§1.56 & I.97-I.98 - March 7, 2003) Lever, A.M.L., "Gene Therapy for HIV Infection," British Medical Bulletin 31. 51(1):149-166 (1995) [Exhibit 31] Wu, C.H. et al., "Targeting Genes: Delivery and Persistent Expression of a 32. Foreign Gene Driven by Mammalian Regulatory Elements in Vivo," The Journal of Biological Chemistry 264(29):16985-16987 (1989) [Exhibit 32] Wagner, E. et al., "Coupling of adenovirus to transferring-polylysine/DNA 33. complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes," Proc. Natl. Acad. Sci. USA 89:6099-6103 (1992) [Exhibit 33] Ruoslahti, E. et al., "Alignment of Biologically Active Domains in the 34. Fibronectin Molecule," The Journal of Biological Chemistry 256(14):7277-7281 (1981) [Exhibit 34] Cristiano, R.J. et al., "Hepatic gene therapy: Adenovirus enhancement of 35. receptor-mediated gene delivery and expression in primary hepatocytes," Proc. Natl. Acad. Sci. USA 90:2122-2126 (1993) [Exhibit 35]

Curiel, D.T. et al."Adenovirus enhancement of transferring-polylysine-

mediated gene delivery," Proc. Natl. Acad. Sci. USA 88:8850-8854 (1991)

Wagner, E. et al., "Influenza virus hemagglutinin HA-2 N-terminal fusogenic

peptides augment gene transfer by transferring-polylysine-DNA complexes:

Toward a synthetic virus-like gene-transfer vehicle," Proc. Natl. Acad. Sci.

Argos, P. et al., "The integrase family of site-specific recombinases: regional

similarities and global diversity," The EMBO Journal 5(2):433-440 (1986)

Brakel et al., [U.S. Patent Application Serial No. 07/446,235 [Exhibit 39]*

36.

37.

38.

39.

Enz-53(D3)

[Exhibit 36]

[Exhibit 38]

USA 89:7934-7938 (1992) [Exhibit 37]

Elazar Rabbani et al. Serial No. 08/978,636 Filed: November 25, 1997 Page 7 (Information Disclosure Statement Under 37 C.F.R. §§1.56 & I.97-I.98 - March 7, 2003) Kessler, C., "Detection of Nucleic Acids by Enzyme-Linked Immuno-Sorbent 40. Assay (ELISA) Technique: An Example for the Developoment of a Novel Nonradioactive Labeling and Detection System With High Sensitivity," in Advances in Mutagenesis Research 1, Obe, G. Ed., Springer Verlag, Berlin, 105-152 (1990) [Exhibit 40] Rigby, P.W. et al., "Labeling Deoxyribonucleic Acid to High Specific Activity 41. in Vitro by Nick Translation with DNA Polymerase," Journal of Molecular Biology 113:237-251 (1977) [Exhibit 41] Saiki, R. et al., "Primer-Directed Enzymatic Amplification of DNA with a 42. Thermostable DNA Polymerase," Science 239:487-491 (1985) [Exhibit 42] Melton, D.A. et al., "Efficient in vitro synthesis of biologically ctive RNA and 43. RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter," Nucleic Acids Research 12(18):7035-7056 (1984) [Exhibit 43] Roychoudhury, R. et al., "Influence of nucleotide sequence adjacent to 44. duplex DNA termini on 3' terminal labeling by terminal transferase," Nucleic Acids Research 6(4):1323-1333 (1979) [Exhibit 44] Cook, A.F. et al., "Synthesis and hybridization of a series of biotinylated 45. oligonucleotides," Nucleic Acids Research 16(9):4077-4095 (1988) [Exhibit 45] Agrawal, S. et al., "Efficient methods for attaching non-radioactive labels to 46. the 5' ends of synthetic oligodeoxyribonucleotides," Nucleic Acids Research 14(15):6227-6245 (1986) [Exhibit 46] Jablonski, E. et al., "Preparation of oligodeoxynucleotide-alkaline 47. phosphatase conjugates and their use as hybridization probes," Nucleic Acids Research 14(15):6115-6128 (1986) [Exhibit 47] Staerz, U.D. and Bevan, M.J., "Hybrid hybridoma producing a bispecific 48. monoclonal antibody that can focus effector T-cell activity," Proc. Natl. Acad. Sci. USA 83:1453-1457 (1986) [Exhibit 48] Fanger, M.W., "Bispecific Antibodies," Critical Reviews in Immunology 49. 12(3,4):101-124 (1992) [Exhibit 49] Enz-53(D3)

Elazar Rabbani et al. Serial No. 08/978,636 Filed: November 25, 1997 Page 8 (Information Disclosure Statement Under 37 C.F.R. §§1.56 & I.97-I.98 - March 7, 2003) Gruber, M. et al., "Efficient Tumor Cell Lysis Mediated by a Bispecific Single 50. Chain Antibody Expressed in Escherichia coli," Journal of Immunology 152:5368-5372 (1994) [Exhibit 50] Holliger, P. et al., ""Diabodies": Small bivalent and bispecific antibody 51. fragments," Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) [Exhibit 51] Anderson, W.F. et al., "Structure of the cro represeor from bacteriophage 52. and its interaction with DNA," Nature 290:754-758 (1981) [Exhibit 52] Palsson, B.O. et al., "Expansion of Human Bone Marrow Progenitor Cells in a 53. High Cell Denstiry Continuous Perfusion System," Biotechnology 11:372368 (1993)] [Exhibit 53] Koller, M.R., et al., "Expansion of Primitive Human Hematopoietic Progenitors 54. in a Perfusion Bioreactor System with IL-3, IL-6, and Stem Cell Factor," BioTechnology 11:358-363 (1993) [Exhibit 54] Koller M.R. et al., "Large-Scale Expansion of Human Stem and Progenitor 55. Cells From Bone Marrow Mononuclear Cells in Continuous Perfusion Cultures," Blood 82(2):378-384 (1993) [Exhibit 55] Stavrianopoulos, J., U.S. Patent No. 4,843,122 issued June 27,1989 56. [Exhibit 56] Engelhardt, D. et al., European Patent No. EP 0 285 057 B1 granted March 57. 1, 1995 [Exhibit 57] Mount, S.M., "A catalogue of splice junction sequences," Nucleic Acids 58. Research 10(2):472 (1982) [Exhibit 58] Mayeda, A. and Oshima, Y., "Beta-globin tanscripts carrying a single intron 59. with three adjacent nucleotides of 5' exon are efficiently spliced in vitro irrespective of intron positon or surrounding exon sequences," Nucleic Acids Research 18(16):4676 (1990)[Exhibit 59] Chu, F.K. et al., "Intervening sequence in the thymidylate synthase gene of 60. bacteriophage T4," Proc. Natl. Acad. Sci. USA 81:3049-3053 (1984) [Exhibit 609] Enz-53(D3)

Elazar Rabbani et al. Serial No. 08/978,636 Filed: November 25, 1997 Page 9 (Information Disclosure Statement Under 37 C.F.R. §§1.56 & I.97-I.98 - March 7, 2003) Chu F.K. et al., "In Vitro Expression of the Intron-containing Gene for T4 61. Phage Thymidylate Synthase," The Journal of Biological Chemistry 260(19):10680-10688 (1985) [Exhibit 61] Muzyczka, N., "Use of Adeno-Associated Virus as a General Transduction 62. Vector for Mammallian Cells," Current Topics in Microbiology and Immunology 158:97-129 (1992)] [Exhibit 62] Rafestin, M.E. et al., "Purification of N-Acetyl D-Glucosamine-Binding 63. Proteins By Affinity Chromatography," FEBS Letters 40(1):62-66 (1974) [Exhibit 63] Lear, J.D. and DeGrado, W.F., "Membrane Binding and Conformational 64. Properties of Peptides Representing the NH2 Terminus of Influenza HA-2," The Journal of Biological Chemistry 262(14):6500-6505 (1987) [Exhibit 64] Kalderon D. et al., "A Short Amino Acid Sequence Able To Specify Nuclear 65. Location," Cell 39:499-509 (1984) [Exhibit 65]

- Stavrianopoulos J.G. et al., "Mechanism of DNA Replication by Highly 66. Purified DNA Polymerase of Chicken Embryo," Proc. Nat. Acad. Sci. USA 69(9):2609-2613 (1972) [Exhibit 66]
- Nitta, T. et al., "Bispecific F(ab')x monomer prepared with anti-CD3 and anti-67. tumor monoclonal antibodies is most potent in induction of cytolysis of human T cells," Eur J. Immunol. 19:1437-1441 (1989) [Exhibit 67]
- Horton, R.M. et al., "Gene Splicing by Overlap Extension Tailor-Made Genes 68. Using the Polymerase Chain Reaction," BioTechniques 8(5):528-535 (1990) [Exhibit 68]
- Horton, R.M. et al., "Engineering hybrid genes without the use of restriction 69. enzymes: gene splicing by overlap extension," Gene 77:61-68 (1989) [Exhibit 69]
- Scharf, S.J. et al., "Direct Cloning and Sequence Analysis of Enzymatically 70. Amplified Genomic Sequences," Science 233:1076-1078 (1986) [Exhibit 70]

Elazar Rabbani et al.
Serial No. 08/978,636
Filed: November 25, 1997
Page 10 (Information Discle

Page 10 (Information Disclosure Statement Under 37 C.F.R. §§1.56 & I.97-I.98 – March 7, 2003)

- 71. Saiki, R.K., et al., "Enzymatic Amplification of Beta-Globin Genomic Sequences and Restriction Site Analysis for Diagnosis of Sickle Cell Anemia," Science 230:1350-1354 (1985) [Exhibit 71]
- 72. Kozak, M.. "Point Mutatiaons Define a Sequence Flanking the AUG Initiator Codon That Modulates Translation by Eukaryotic Ribosomes," Cell 44:283-292 (1984) [Exhibit 72]
- 73. Joshi, S. et al., "Inhibition of Human Immunodeficiency Virus Type 1 Multiplication by Antisense and Sense RNA Expression," <u>Journal of Virology</u> 65(10):5524-5530 (1991)] [Exhibit 73]
- 74. Sczakiel, G. et al., "Specific inhibition of immunodeficiency virus type 1 replication by RNA transcribed in sense and antisense orientation from the 5'-leader/gag region," <u>Biochemical and Biophysical Research Communication</u> 169(2):643-651 (1990) [Exhibit 74]
- 75. Dunn, J.J. and Studier, F.W., "Complete Nucleotide Sequence of Bacteriophage T7 DNA and the Locations of T7 Genetic Elements," <u>J. Mol.</u> Biol. 166:477-535 (1983)] [Exhibit 75]
- 76. Sandig V. et al., "A phage t& class-III promoter functions as a polymerase II promoter in mammalian cells," Gene 131:255-259 (1993) [Exhibit 76]
- 77. Harrison G.S. et al., "Inhibition of Human Immunodeficiency Virus-1 Production Resulting from Transduction with a Retrovirus Containing an HIV-Regulated Diptheria Toxin A Chain Gene," Human Gene Therapy 3:461-469 (1992)] [Exhibit 77]
- 78. Manser, T. and Gesteland, R.F., "Human U1 Loci" Genes for Human U1 RNA Have Dramtically Similar Genomic Environments," Cell 29:257-264 (1982)] [Exhibit 78]
- 79. McBurney M.W. et al., "The mouse Pgk-1 gene promoter contains an upstream activator sequence," <u>Nucleic Acids Research 19(20):5755-5761 (1991) [Exhibit 79]</u>
- 80. Laurence, J. et al., "Induction of Chronic Human Immunodeficiency Virus Infection Is Blocked In Vitro by a Methylphosphonate Oligodeoxynucleoside

Elazar Rabbani et al.
Serial No. 08/978,636
Filed: November 25, 1997

Page 11 (Information Disclosure Statement Under 37 C.F.R. §§1.56 & I.97-I.98 – March 7, 2003)

Targeted to a U3 Enhancer Element," The Journal of Virology 65(1):213-219 (1991) [Exhibit 80]

81. Soeiro, R. and Darnell, J.E., "Competition Hybridization by "Pre-saturation" of HeLa Cell DNA," J. Mol Biol 44:551-562 (1969) [Exhibit 81]

The above eighty-one documents [Exhibits 1-81] were cited in the instant specification.

A completed Form PTO-1449 listing the eighty-one above-submitted documents is also attached hereto as Exhibit A.

By this voluntary citation of art, Applicants and their attorney are requesting that the documents be made of record in the present application.

The above citation of documents is not a representation that these documents constitute a complete or exhaustive listing, nor that the above listing necessarily includes the closest or most relevant documents, nor are these documents necessarily a complete listing of all documents known to Applicants or their attorney. It is simply a voluntary citation of documents made in good faith, which is not intended to serve in any way as a substitute for the Examiner's own search.

In view of the general and specific features described and claimed in the present application, Applicants respectfully submit that the present invention is neither disclosed nor suggested by the documents referred to above and is thus patentably distinct thereover. Furthermore, Applicants do not believe, and do not submit, by the citation of these references, that these documents, either by themselves or in combination with other documents, render the invention *prima facie* obvious under the duty of disclosure rules.

Applicants respectfully request that the Examiner make the above-submitted documents of record in the instant application. Applicants further request that the

Elazar Rabbani et al. Serial No. 08/978,636

Filed: November 25, 1997

Page 12 (Information Disclosure Statement Under 37 C.F.R. §§1.56 & I.97-I.98 – March 7, 2003)

Examiner consider these documents as any of them may relate to the instant application.

The fee under 37 C.F.R. §1.17(p) for filing this Information Disclosure Statement is \$180.00. The Patent and Trademark Office is hereby authorized to charge the amount of this fee (and any other fees in connection with this IDS) to Deposit Account No. 05-1135, or to credit any overpayment thereto.

Respectfully submitted,

Ronald C. Fedus

Registration No. 32,567 Attorney for Applicants

ENZO THERAPEUTICS, INC. c/o Enzo Biochem, Inc. 527 Madison Avenue (9th Fl.) New York, New York 10022 Telephone: (212) 583-0100

Fax: (212) 583-0150

^{*} No document or publication is being submitted for this Exhibit due to technical difficulties.

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Elazar Rabbani et al.

Serial No.

08/978,636

Group Art Unit: 1635

Filed:

November 25, 1997

Examiner: Mary M. Schmidt

Title: NON-NATIVE POLYMERASE ENCODING

NUCLEIC ACID CONSTRUCT

RECEIVED

MAR 1 3 2003

TECH CENTER 1600/2900

TRANSMITTAL INFORMATION DISCLOSURE STATEMENT

COMMISSIONER FOR PATENTS Washington, D.C. 20231

Sir:

Transmitted herewith is an Information Disclosure Statement which is being filed in accordance with 37 C.F.R. §§ 1.56 and 1.97-1.98. The items listed on Form PTO-1449, a copy of which is enclosed, may be deemed to be pertinent to the above-identified application and are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

1. [] For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:

EXPRESS MAIL CERTIFICATE

"Express Mail" Label No. EL647884447US

Deposit Date

March 7, 2003

I hereby certify that this paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and

Trademarks, Washington DC 20231.

Ronald C. Fedus

Reg. No. 32,567

Date

MAN 7 2003

Elazar Rabbani et al. Serial No.: 08/978,636 Filed: November 25, 1997 Page 2 [Information Disclosure Statement] -- March 7, 2003 2. [] For each of the following items listed on the enclosed copy of form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application. 3. [] Any copy of the items on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in the prior [] Divisional or [] Continuation-In-Part application under 37 C.F.R. §1.60, U.S. Serial No. , filed _____. 4. [] No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with: 37 C.F.R. ?1.97(b)(1), within three months of the filing date of the [] above-identified application. 37 C.F.R. ?1.97(b)(2), within three months of the date of entry into [] the national stage as set forth in ?1.491 in an international application. 37 C.F.R. ?1.97(b)(3), before the mailing date of a first Office action the merits. on 5. [] No fee is due under 37 C.F.R. ?1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one of the certifications pursuant to 37 C.F.R. ?1.97(e) set forth in paragraph 9 below. 6. [x] A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a notice of allowance (where there has been no prior final action): A check in the amount of \$240.00 is enclosed in payment of the fee. [] Charge the fee to Deposit Account No. 05-1135, Order No. ENZ-[x] 53(D3). A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Elazar Rabbani et al. Serial No.: 08/978,636 Filed: November 25, 1997 Page 3 [Information Disclosure Statement] -- March 7, 2003 7. [] A fee is due under 37 C.F.R. §1.17(i)(1) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final action or a notice of allowance, whichever comes first, but before payment of the issue fee, and is accompanied by: one of the certification pursuant to 37 C.F.R. §1.97(e) set forth in a. paragraph 9 below; and the attached petition requesting consideration of this Information b. Disclosure Statement; and the fee due under 37 C.F.R. §1.17(i)(1) which is paid as set forth in C. paragraph 10 below. 8. [] A fee is due under 37 C.F.R. §1.17(i)(1) for this Information Disclosure Statement since it is being filed in compliance with: a. [] 37 C.F.R. §1.313(b)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue; b. [] 37 C.F.R. §1.313(b)(5), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To Withdraw Application From Issue. c. [] The fee due under 37 C.F.R §1.17(i)(1) is paid as set forth in paragraph 10 below. 9. [] I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. [] I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in ?1.56(c) more than three months prior to the filing of this Information Disclosure Statement. Enz-53(D3)

Elazar Rabbani et al.
Serial No.: 08/978,636

Filed: November 25, 1997
Page 4 [Information Disclosure Statement] -- March 7, 2003

- 10. [] A check in the amount of \$130.00 is enclosed in payment of the fee due under 37 C.F.R. §1.17(i)(1).
 - [X] Charge the fee under 37 C.F.R. §1.17(i)(1) to Deposit Account No. 05-1135. Order No. ENZ-53(D3). A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
 - [x] The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 05-1135. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Dated: March 7, 2003

By:

RONALD C. FEDUS

Registration No. 32,567 Attorney for Applicants

Respectfully submitted,

Mailing Address:

ENZO THERAPEUTICS, INC. c/o Enzo Biochem, Inc. 292 Madison Avenue, 9th Floor New York, New York 10022 Telephone: (212) 583-0100

Telefax: (212) 583-0150

Form PTO-14	49 L).S. [Эера	rtmer	nt of	Com	merc	e	Atty. E ENZ-5	Oocket No.	Se	rial No. 08	3/978,6	36
(REV. 8-83)	Pate	nt an	d Tra	adem	ark C	ffice	:		LIVE					
INFOF								1						
10.0	se se	veral	l she	ets if	nece	essar	γ)		Applica	ants: Elazar Rabba	ani et al.	•,		
MAR 0 7 2003	2 0 0													
1914A U 7 ZUUJ - -	Cr.								Filed: 1997	November 25,	Gr	oup: 163	35	
Company of the Compan							U.S	. PAT	ENT DOCUM	MENTS		- 	FILIN	
EXAMINER					.	252		`	DATE	NAME	CLASS	SUB CLASS	DAT APPI PRIA	E IF
INITIAL		5 5	CUM 1	ENT 6	NUM 6	3 BEK	2	0	DATE 11/24/92	Wu, G.Y.				<u> </u>
		4	6	8	7	7	3	2	8/18/87	Ward, D.C.				
		5	2	6	0	4	3	3	11/9/93	Engelhardt, D.				
			7	1	1	9	5	5	12/8/87	Ward D.C.		-		
·	-	4			1	0	6	0	8/31/93	Engelhardt D.	<u> </u>			
		5	2	4						Stavrianopoulos				
		4	7	0	7	4	4	0	11/17/87	J.				
		· 				F	ORE	IGN F	PATENT DOC	UMENTS	<u> </u>			
		DC	CUN	MENT	. NUV	ивег	₹		DATE	COUNTRY	CLASS	SUB CLASS	TRAN LATIC YES	
	EP	0	2	8	5	0	5	7B	3/1/05					
	W O	9	5	2	6	2	0	0	10/5/95					
									O sala a a Titl	- Data Postinant	Pages	Etc.)		
									236 (1993)	e, Date, Pertinent	rages,	L(C.)		
	-				l., <u>Ge</u> r									<u> </u>
	-									8122-8126 (1986)			_	
	ļ	!								485-8493 (1989)				
		T:-		1. Cl	ar., <u>:N</u> l	ICICIC	ACIU	3 IXCS	<u> </u>					
					1 1/10	ماء ماء	in E	252 522	Jagy 217:47 6	7 (1003)				
EXAMINER					l., <u>M</u> e	thods	in E	nzymo	DATE CON		· · · · · · · · · · · · · · · · · · ·			

orm PTO-1449	U.S. D)epartmei	nt of C	Commer	ce		Atty. C ENZ-5	Docket No.	Seri	ial No. 08	978,636
REV. 8-83) Pa	atent an	d Tradem	ark Of	ffice			.				
INFORM	1ATION	DISCLOS	SURE C	CITATIO	N						
(use	e several	sheets if	neces	ssary)			Applic	ants: Elazar Rab	bani et al.		
MAR 0 7 2003	· ·					-	Filed:	11/25/97	Gro	oup: 163	5
				U.	S. PA	TENT [OCUN	MENTS			1 50 110
									CLASS	SUB	FILING DATE IF APPRO-
XAMINER NITIAL	DO	CUMENT	NUME	BER	- 	DAT	Ε	NAME	CLASS	CLASS	PRIATE
					_						
				1, 10, 7							
	<u>'</u>	<u> </u>	<u>-</u>	FOR	EIGN	PATEN	T DOC	UMENTS			
	DO	OCUMEN'	T NUN	ИBER		DA	ΛTE	COUNTRY	CLASS	SUB CLASS	TRANS- LATION YES NO
										<u> </u>	
										[to]	ļ
	0.	THER DO	CUME et al. I	NTS (Ir	ncludir t Acad	ng Auth I. Sci. U	nor, Tit .S.A. 8	le, Date, Pertine 1: 2035-2039 (1984	ent Pages, 4)	E(C.)	
		orris, C.E.							<u> </u>		
·								53-2664 (1987)			
								53-2664 (1987)	10.61.68 (1	1991)	
	ł							olecular Biology 2			Ae"in
	Da	hlberg, J.I	E. and I	Lund, E.,	, "The (Genes a	nd Tran r Small	Nuclear Ribonucle	ajor Small N coprotein Pa	nuclear KNA articles, Bira	nstiel, M. Ed.,
	l Cn	ringer Ver	lag Re	erlin Hei	idelberg	g. NY. 1	London,	Paris, Tokyo, pp.	30-10 (130	10)	
	Zi	eve, G.W.	and Sa	utereau,	R.A., <u>I</u>	<u> Biochen</u>	nistry ar	id Molecular Biolo	ogy 25(1):1-		
EXAMINER						1		NSIDERED			
	Initial i	f citation t in confo	considermand	dered, v	whether	er or no	ot citat	tion is in conformude copy of this	nance with s form wit	n MPEP 60 h next cor)9; Draw li mmunicatio

orm PTO-144	9 U.S	5. De	epar	tmen	t of (Comr	merce	?			Docket No. 53(D3)		Seria	1 No. 08/	978,63	86
REV. 8-83) F	atent	and	i Tra	idem	ark O	ffice					•					
INFORÎ	MATIC	ON [DISC	LOS	URE	CITA	AOIT.									
(US	e seve	eral	shee	ets if	nece	ssar	y)			Applic	ants: Elazar Rabb	oani et	t al.			
70° 8	р -ме ^г															
MAR 0 7 2003	.)) 9.									Filed:	11/25/971995		Grou	p: 1635	5	
) - Je.			_								MENTO					
							U.S	PA7	ENT	DOCU	WENTS				FILIN	
The second secon														SUB	DATE	
XAMINER				 1 	. .	חבת			DA	TE	NAME	CL	ASS	CLASS	PRIA	
NITIAL		DOC 4	8 8	ENT 4	NUM 3	BEK 1	2	2		27/89	Stavrianopoulos	S				
		+		-		<u> </u>	-									
													<u></u>			
																<u></u>
		-														
1		Ì		}	ļ	i F	∣ ORE	। IGN ।	I PATE	NT DO	CUMENTS	- ₁		· 		
															TRAN	S-
														SUB	LATIO	
		DO	CUI	MEN	r NU	MBE	R		0	DATE	COUNTRY	CLA	ss	CLASS	YES	N(
												-				
								_	-	<u> </u>						
					<u> </u>											-
	<u>-</u>							i,							ļ	
!		רס '	THEF	R DO	сὑм	ENT	s (Inc	ludir	ıg Aı	thor, T	itle, Date, Pertine	nt Pag	ges, E	communic	eations in	
		Izai	nt, J.	G. an	id Sar	delli, Anti	A.D., sense	"Ant	isens	e Inhibito DNA, M	on of RNA Splicing, elton, D.A., Ed., Co	ld Spri	ing Ha	rbor Labor	ratory, p	p.
		1 1 1 1	1 1/10	(108	(8)											
											lular Biology 9(8):3				222	
		Ch	en, C	C.J. et	al., "	Inhib	ition (of HIV	V-1 R	demy of	on by Novel Multitar Sciences 660:271-2	get Ril 73 (199	bozym 92)	ies, Antis	ense	<u></u>
		Str.	ategi ou Z	es, Ar et al	nnals Gen	or the	: <u>new</u>):33-3	1 ork 9 (19	94)	defity of	Sciences 660:271-2		<u>, </u>			
	 	1								i. USA 9	<u>90</u> :8000-8004 (1993)				
		1												 _		
]									<u>1(4)</u> :621-633 (1992)	, .				
		1			, Gene							·				- -
		Sc	zakie	el, G.	et al.	, <u>Jour</u>	nal of	Viro	logy	<u>66(9)</u> :55	76-5581 (1992)					
		1									ONSIDERED					
EXAMINER									1						09; Dra mmunio	

orm PTO-144	9 U.S	S. De	epar	tmer	t of	Comi	merce	9			ocket No. (D3)	Se	rial No. 08	/978,636
REV. 8-83) F	Patent	and	l Tra	dem	ark C	ffice								
TNFOR	MATI	ON E	DISC	LOS	URE	CITA	TION	l						
Tus Yus	e sev	eral	shee	ets if	nece	essar	y)		Apr	olicar	nts: Elazar Rabb	oani et al		
MAR 0 7 2003	on .								5:1		1/25/071005	Gr	oup: 163	<u> </u>
e Constant									File	d: 1	1/25/971995		<u> </u>	
** ** ** ** ** ** ** ** ** ** ** ** **							U.S.	PAT	ENT DOC	UME	ENTS			FILING
										!			SUB	DATE IF APPRO-
XAMINER VITIAL		DOC	UME	ENT	NUM	BER			DATE	1	NAME	CLASS		PRIATE
1117.														
				-										
·		· · · · · ·				F	ORE	GN F	PATENT D	OCU	JMENTS			
		DO	CUM	1ENT	. NUI	MBEF	₹		DATE		COUNTRY	CLASS	SUB CLASS	TRANS- LATION YES NO
				T			1							
		<u> </u>	-			-				·				
		OT	 HER	DOC	CUMI	ENTS	l (Incl	l ludin	l g Author,	Title	Date, Pertiner	nt Pages	, Etc.)	<u> </u>
											(<u>1</u>):468-472 (1991			
										irnal 8	<u>8(12</u>):3861-3866	(1303)	 	
									93 (1994)		5.0153 (1096)			
											5-8153 (1986)			
									letin 51(1):			16007 (10	80)	
											<u>y 264(29)</u> :16985-	10987 (19	(O7)	
											99-6103 (1992)	7 7001 (1)	<u> </u>	
		Ruc	oslahi	ti, E.	et al.,	The.	Journa	al of I			istry 256(14):727	/-/281 (19		
									_		SIDERED			

orm PTO-144	19 U	J.S. E	Depar	rtmer	nt of	Comr	merce	 e		Docket No. 53(D3)		Seria	al No. 08	/978,63	36
REV. 8-83)	Pate	nt an	d Tra	adem	ark C	ffice									
INEOR	MAT	ION.	DISC	CLOS	URE	CITA	TION								
, (ur	se se	veral	sne	ets it	nece	essary	/)		Appli	cants:Elazar	Rabbar	ni et al.			
MAR 0 7 200	3 တို့	\$							Filed:	11/25/97	<u> </u>	Grou	 up: 163	 5	<u>,</u>

						· · · · -	U.S.	PAT	ENT DOCU	MENTS			<u></u>	FILIN	IG
EXAMINER		200	CLIM	ENT	NII 1 N /I	RER			DATE	NAME		CLASS	SUB CLASS	DATI APPF PRIA	E IF RO-
NITIAL		000	COM	EINI	140141	BEN	1		DATE		<u> </u>				
				<u> </u>											
	 -—-			-											
		<u> </u>			-										
	<u> </u>	 	i 		ļ 	 	OREI	GN F	ATENT DO	CUMENTS		<u> </u>	·		
		DO	ocui	MEN	r nui	MBEF	₹		DATE	COUNT	·RY	CLASS	SUB CLASS	TRAN LATIC YES	
			_			_	_	-							
							`	ا	Author T	itle, Date, P	ertinent Pertinent	t Pages, l	 Etc.)	1	
		Cr	THEF istian	o, R.J	et a	LN 18	c. Nat	il. Aca	ad. Sci. USA	90:2122-212	6 (1993)	<u>- · · - · · · · · · · · · · · · · · · ·</u>			
		1								8850-8854 (19					_
		· I								7934-7938 (19					
	-								<u>5(2):433-440</u>					<u>, </u>	
		Ar Se	n Exa ensitiv 990)	mple vity,"	for the in <u>Ad</u>	e Devi vance:	elopor s in M	ment (lutage	of a Novel Nonesis Research	me-Linked Ir onradioactive ch 1, Obe, G.	Ed., Spri	z and Dete	Chon Syste	2111 11 1411	• • • • • • • • • • • • • • • • • • • •
		Ri	igby,	P.W.	et al.,	Journ	al of N	Molec	cular Biology	<u>113</u> :237-251	(1977) 				
									1 (1985)				······		
		M	lelton	, D.A	et al.	, Nuc	leic A	cids I	Research 12(<u>18</u>):7035-705	6 (1984)				
							· · · · ·		DATE C	ONSIDERED)				

to applicant.

Sheet 6 of 10 Serial No. 08/978,636 Atty. Docket No. Form PTO-1449 U.S. Department of Commerce ENZ-53(D3) (REV. 8-83) Patent and Trademark Office INFORMATION DISCLOSURE CITATION (use several sheets if necessary) Applicants: Elazar Rabbani et al. Group: 1635 Filed: 11/25/97 U.S. PATENT DOCUMENTS **FILING** DATE IF APPRO-SUB CLASS CLASS **PRIATE** NAME DATE DOCUMENT NUMBER

	 	1 		· · ·	FC	DREI	GN PA	TENT DO	CUMENTS				<u>. </u>
	DO	CUM	ENT	NUM	BER			DATE	COUNTRY	CLASS	SUB CLASS	TRAN LATIO YES	
 <u> </u>						-							

MAR 0 7 2003

EXAMINER

EXAMINER

INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

FXAMINER	DATE CONSIDERED
	Holliger, P. et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993)
	Gruber, M. et al., <u>Journal of Immunology 152</u> :5368-5372 (1994)
	Fanger, M.W., Critical Reviews in Immunology 12(3,4):101-124 (1992)
	Staerz, U.D. and Bevan, M.J., <u>Proc. Natl. Acad. Sci. USA 83</u> :1453-1457 (1986)
	Jablonski, E. et al., Nucleic Acids Research 14(15):6115-6128 (1986)
	Agrawal, S. et al., Nucleic Acids Research 14(15):6227-6245 (1986)
·	Cook, A.F. et al., <u>Nucleic Acids Research 16(9):4077-4095</u> (1988)
	Roychoudhury, R. et al., Nucleic Acids Research 6(4):1323-1333 (1979)
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 7 of 10 Serial No. 08/978,636 Atty. Docket No. Form PTO-1449 U.S. Department of Commerce ENZ-53(D3) (REV. 8-83) Patent and Trademark Office INFORMATION DISCLOSURE CITATION ., . (use several sheets if necessary) Applicants: Elazar Rabbani et al. Group: 1635 Filed: 11/25/97 U.S. PATENT DOCUMENTS **FILING** DATE IF APPRO-SUB **EXAMINER** CLASS **CLASS PRIATE** NAME DATE DOCUMENT NUMBER INITIAL FOREIGN PATENT DOCUMENTS TRANS-**LATION** SUB NO YES COUNTRY CLASS DATE DOCUMENT NUMBER CLASS OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Anderson, W.F. et al., Nature 290:754-758 (1981) Palsson, B.O. et al., <u>Biotechnology 11</u>:372368 (1993) Koller, M.R., et al., <u>BioTechnology 11</u>:358-363 (1993) Koller M.R. et al., <u>Blood 82(2)</u>:378-384 (1993) Mount, S.M., Nucleic Acids Research 10(2):472 (1982) Mayeda, A. and Oshima, Y., Nucleic Acids Research 18(16):4676 (1990) Chu, F.K. et al., Proc. Natl. Acad. Sci. USA 81:3049-3053 (1984) Chu F.K. et al., The Journal of Biological Chemistry 260(19):10680-10688 (1985) DATE CONSIDERED **EXAMINER** *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication

to applicant.

Form PTO-1449	U.S. [)epartme	ent of C	Commerce		Atty. Docket No. ENZ-53(D3))				Serial No. 08/978,636			
(REV. 8-83) Pat	tent an	d Trader	mark Of	ffice									
INFORMA													
		l sheets	if neces	ssary)		Appli	cants: Elazar Rab	bani et	al.				
MAR 0 7 2003 %									<u> </u>	162			
						Filed:	11/25/97		Gro	up: 163			
				U.S. F	PATENT	DOCU	MENTS			<u> </u>	CUIN	IC	
											FILIN		
EXAMINER				250		TC	NAME	CLA	ASS	SUB CLASS	APP		
INITIAL	DOC	CUMENT	NUME	3ER	DA	i E	NAME		<u>_</u>		1100		
			-						<u>-</u>				
			-									_	
									-				
									-				
	11/11 13									1			
							OLIBATAITC						
				FOREIG	N PATE	NT DO	CUMENTS			-			
								:		CUR	TRAN LATIO		
	- 1			1RFR		ATE			.	SUB	·	NO	
	DC	CUMEN	II NUN	10411			COUNTRY	CLAS	SS	CLASS	YES		
	DC	CUMEN					COUNTRY	CLAS	SS	CLASS	165		
	DC	CUMEN	II NOIV				COUNTRY	CLAS	S	CLASS	165		
	DC	CUMEN	II NOIV				COUNTRY	CLAS	SS	CLASS	165		
											163		
	01	THER DO	CUME	NTS (Includ	ding Au	thor, Ti	tle, Date, Pertine	nt Pag	es, E	tc.)	163		
	O1 Mu	THER DC	OCUMEI N., Curre	NTS (Includ	ding Au Microbi	thor, Ti	tle, Date, Pertine	nt Pag	es, E	tc.)	YES		
	O1 Mu Rai	THER DC	OCUMEI N., Curre E. et al.,	NTS (Includent Topics in FEBS Letter	ding Au Microbi	thor, Ti ology ar 62-66 (1	tle, Date, Pertine ad Immunology 158:	nt Pag 97-129	es, E	tc.)			
	O1 Mu Rai	rHER DC zyczka, N festin, M.I	DCUMEI N., Curre E. et al.,	NTS (Includent Topics in FEBS Letter ado, W.F., T	ding Au Microbi ers 40(1):	thor, Ti ology ar 62-66 (1 al of Bio	tle, Date, Pertine	nt Pag 97-129	es, E	tc.)			
	O1 Mu Rai	rHER DC zyczka, N festin, M.I ar, J.D. an Ideron D.	DCUMEI N., Curre E. et al., and DeGra	NTS (Includent Topics in FEBS Letter ado, W.F., Topics in Sell 39:499-5	ding Au Microbi ers 40(1): The Journ	thor, Ti ology ar 62-66 (1 al of Bio	tle, Date, Pertine ad Immunology 158: 974)	nt Pag 97-129	es, E (199	tc.)			
EXAMINER	O1 Mu Rai	rHER DC zyczka, N festin, M.I ar, J.D. an Ideron D.	DCUMEI N., Curre E. et al., and DeGra	NTS (Includent Topics in FEBS Letter ado, W.F., Topics in Sell 39:499-5	ding Au Microbi ers 40(1): The Journ 09 (1984 Nat. Ac	thor, Ti ology ar 62-66 (1 al of Bio) ad. Sci.	tle, Date, Pertine ad Immunology 158:	nt Pag 97-129	es, E (199	tc.)			

REV. 8-83)			spart	meni	() (Comr	merc	е			Docket No. 53(D3)		Sena	i No. 08/	370,00	
(EV. 8-83)	Pater	nt and	Trac	dema	ırk O	ffice										
INFOR	MAT	ION	olsci	LOSU	JRE (CITA	TION	i	ļ							
(ne	se se	veral	shee	ts IT	nece	ssary	y I			Applic	ants: Elazar Rat	obani e	et al.			
MAR 0 7 2003										Filad:	11/25/97		Grou	ıp: 163	 5	
4) (
							U.S	. PA	TENT	DOCUI	MENTS		.		FILIN	 G
XAMINER						050			D 4.T		NAME	CL	ASS	SUB CLASS	DATE APPE PRIA	IF RO-
NITIAL		DOC	UME	1 TM	10M	BER			DAT		NAIVIE					
					Ħij											
									-							
										<u> </u>						
					1	 	ORE	IGN	PATE	NT DO	CUMENTS			<u> </u>		<u></u>
		DO	CUM	1ENT	NUI	MBEF	3		D	ATE	COUNTRY	CLA	ss	SUB CLASS	TRAN LATIO YES	
			T		1											
		_			-				-							
			-	-	-	_		-					. <u>.</u>			
		ОТ	HER	DOC	 :UMI	 ENTS	 S (Inc	 :ludir	 ng Au1	thor, Ti	tle, Date, Pertin	l ent Pag	ges, E	tc.)	l 	
		Nitt	a, T.	et al.,	Eur	J. Imi	muno	1. 19:	1437-1	441 (198	39)	<u> </u>				
		Hor	ton, I	R.M.	et al.,	BioT	Techn	iques	<u>8(5):5</u>	28-535	(1990)		<u>,</u>			
	-	Hor	ton, l	R.M.	et al.,	Gen	e 77:6	51-68	(1989)							
		Sch	arf, S	S.J. et	t al., <u>s</u>	Scien	ce 23	<u>3</u> :107	6-107	3 (1986)						
	-	Sai	ki, R.	K., et	al., <u>S</u>	Scienc	ce 230	0:135	0-1354	1 (1985)						
	+-	Ko	zak, N	М <u>С</u>	ell 44	:283-	292 (1984)	 							
						·			D	ATE CO	NSIDERED					

Sheet 10 of 10

orm PTO-1449	U.S.	Depar	tmer	nt of	Comr	nerce		•	Docket No. 53(D3)	Seria	al No. 08/	978,63	6
REV. 8-83) Pa	itent ar	nd Tra	adem	ark C	ffice								
INFORM													
	severa							Applic	cants: Elazar Rabi	pani al.			
MAR 0 7 2003								Filed:	11/25/97	Gro	up: 163	5	
						U.S.	PAT	ENT DOCU	MENTS				
XAMINER	D.C.	CUM		NII IN	IRER			DATE	NAME	CLASS	SUB CLASS	FILING DATE APPR PRIAT	E IF RO-
VITIAL	DC	T	ENI	INCIV	DEIN			<i>D</i>					
		-											
		-			-		<u></u> -						
				-	-								
					 _ F	OREI	GN I	ATENT DO	CUMENTS		'	'	
		ocui	MEN ⁻	T NU	MBEF	3		DATE	COUNTRY	CLASS	SUB CLASS	TRANS <u>LATIO</u> YES	
			- - 										
							-						:
į		 OTHEF	l R DO	CUM	ENTS	l S (Incl	l ludin	l g Author, T	itle, Date, Pertine	ent Pages,	Etc.)		-
	Jo	oshi, S	. et al	., <u>Jou</u>	rnal of	f Virol	ogy (<u>65(10</u>):5524-5	530 (1991)			(1000)	
									Research Communi	cation 169(2	<u></u>	(177U)	
	D	Dunn, J	.J. ar	nd Stu	dier, I	F.W., <u>J</u>	. <u>М</u> с	l. Biol. 166:4	77-535 (1983)				
<u> </u>	S	andig	V. et	al., <u>G</u>	ene 13	<u>31</u> :255	-259	(1993)					_ <u>_</u>
	F	Harriso	n G.S	et al	., <u>Hu</u> r	nan Ge	ene T	herapy 3:461	-469 (1992)				
	N	Manser	, T. a	nd Ge	stelan	d, R.F	., <u>Ce</u>	11 29:257-264	(1982)				
	N	McBur	ney N	1.W. 6	et al.,	Nuclei	c Ac	ids Research	<u>19(20)</u> :5755-5761 (1991)			
	l l):213-219 (1991)				
								Biol 44:551-					
EXAMINER						<u>. </u>			ONSIDERED				
	Initial	l if cit	ation confo	cons	sidere	ed, wh	neth	er or not cita nsidered. In	ation is in conform	mance with s form wit	n MPEP 6 h next co	09; Drav mmunic	w lir atio